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Abstract
Chromosomal aberrations were comparatively assessed in nuclei extracted from synovial tissue,
primary-culture (P-0) synovial cells, and early-passage synovial fibroblasts (SFB; 98% enrichment; P-1,
P-4 [passage 1, passage 4]) from patients with rheumatoid arthritis (RA; n = 21), osteoarthritis (OA;
n = 24), and other rheumatic diseases. Peripheral blood lymphocytes (PBL) and skin fibroblasts (FB)
(P-1, P-4) from the same patients, as well as SFB from normal joints and patients with joint trauma (JT)
(n = 4), were used as controls. Analyses proceeded by standard GTG-banding and interphase
centromere fluorescence in situ hybridization. Structural chromosomal aberrations were observed in
SFB (P-1 or P-4) from 4 of 21 RA patients (19%), with involvement of chromosome 1 [e.g.
del(1)(q12)] in 3 of 4 cases. In 10 of the 21 RA cases (48%), polysomy 7 was observed in P-1 SFB. In
addition, aneusomies of chromosomes 4, 6, 8, 9, 12, 18, and Y were present. The percentage of
polysomies was increased in P-4. Similar chromosomal aberrations were detected in SFB of OA and
spondylarthropathy patients. No aberrations were detected in i) PBL or skin FB from the same patients
(except for one OA patient with a karyotype 45,X[10]/46,XX[17] in PBL and variable polysomies in
long-term culture skin FB); or ii) synovial tissue and/or P-1 SFB of normal joints or of patients with joint
trauma. In conclusion, qualitatively comparable chromosomal aberrations were observed in synovial
tissue and early-passage SFB of patients with RA, OA, and other inflammatory joint diseases. Thus,
although of possible functional relevance for the pathologic role of SFB in RA, these alterations
probably reflect a common response to chronic inflammatory stress in rheumatic diseases.
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Human rheumatoid arthritis (RA) is characterized by
chronic inflammation and destruction of multiple joints,
perpetuated by an invasive pannus tissue. Activated syn-
ovial fibroblasts (SFB), whether reversibly stimulated by
the inflammatory microenvironment [1–8] or irreversibly
transformed [2–7;9–11], are a major component of the
pannus and contribute to the joint destruction by secretion
of proinflammatory cytokines and tissue-degrading
enzymes [1].
While specific chromosomal aberrations (e.g. mosaic
trisomy/polysomy 7; +7) are of particular interest with
regard to malignant transformation and biological behavior
of cells, (for example invasiveness, by analogy with obser-
vations in hematological malignancies and solid tumors
[12]), recent evidence indicates that chromosomal abnor-
malities may also be of biological relevance in nontrans-
formed cells, including synovial cells derived from patients
with RA [13–18].
To date, analyses of +7 have been carried out either in
nonseparated synovial cells (including contaminating
inflammatory cells) or in passaged SFB [13–19]. Thus, the
main goals of the present study were: i) to identify the full
extent of structural and numerical chromosomal aberra-
tions (see below) in primary-culture (P-0) synovial cells
(collagenase digest), and early passages of isolated SFB
(98% enrichment; P-1, P-4); ii) to compare these alter-
ations in matched peripheral blood, synovial membrane,
and skin of RA patients; iii) to analyze the specificity of the
aberrations for RA by comparison with other rheumatic
diseases (inflammatory/degenerative) and normal joints or
joints that had undergone trauma; and iv) within synovial
and skin fibroblasts (FB), to differentiate in vivo alteration
from in vitro growth selection.
Materials and methods
Patients
Patients with RA (n = 21), OA (n = 24), or spondylarthro-
pathies (n = 3; consisting of one case of ankylosing
spondylitis and two of psoriatic arthritis), villonodular syn-
ovitis; systemic lupus erythematosus; juvenile rheumatoid
arthritis; undifferentiated monoarthritis, and reactive arthri-
tis (n = 1 each; Supplementary material) were classified
according to criteria from the American College of
Rheumatology/American Rheumatism Association or the
European Spondylarthropathy Study Group [20–24]. Syn-
ovial tissue/cells from four patients with either no joint
disease (postmortem samples) or recent joint trauma, and
skin samples from four normal donors (derived from plastic
surgery of the abdominal wall; mean sample size approxi-
mately 20 cm2), were used as controls (Supplementary
material).
Inflamed synovial tissue, heparinized peripheral blood, and
skin (from the edge of the surgical incision; approximately
0.3–0.6 cm2 in RA and OA) were obtained during open
joint replacement surgery or arthroscopic synovectomy
with the approval of the responsible ethics committees.
Paired blood samples were immediately transferred to the
Institutes of Human Genetics, Friedrich Schiller University
Jena or University of Leipzig, for lymphocyte culture and
karyotype/FISH analysis. Synovial tissue and skin were
placed in cell culture medium at ambient temperature and
subjected to tissue digestion within 2 h.
Tissue digestion, cell culture, and fibroblast isolation
Isolation/fluorocytometry of primary-culture SFB was per-
formed as described elsewhere [25,26], resulting in
enrichment of SFB (Thy-1+: RA 72.1%, n = 13; OA
71.5%,  n = 15; and prolyl 4-hydroxylase+: RA 80.3%;
n = 9; OA 93.1%, n = 9), with a contamination of <2%
leukocytes or endothelial cells.
Primary-culture normal skin FB were prepared as pub-
lished previously [25].
GTG-banding and fluorescence in situ hybridization
Peripheral blood lymphocytes (PBL) were analyzed using
standard methods [19]. Synovial and skin FB were sub-
jected to colcemid, hypotonic treatment, fixation with
methanol/acetic acid, and air-drying. GTG-banding was
performed according to standard protocols [27] on
10–50 metaphases/case. Karyotypes were described in
accordance with the International System for Human
Cytogenetic Nomenclature (ISCN) 1995 [28].
Nuclei were extracted from formalin-fixed/paraffin-embed-
ded or cryofixed tissue by the method of Liehr et al
[29,30]. Fluorescence in situ hybridization (FISH) with
centromere probes was performed in interphase nuclei
using standard protocols (VYSIS, Downers Grove, IL,
USA). Four centromere probes were selected according
to the results of GTG banding.
Data were analyzed and depicted either on the basis of
the total polysomy of nuclei, i.e. focusing on the total gain
of potential gene transcription units, or selectively on the
basis of trisomic nuclei, focusing on mitotic nondisjunction
as a possible underlying mechanism.
Statistical analysis
Data were analyzed using the multigroup Kruskal–Wallis
test, the nonparametric Mann–Whitney U test, and the
Spearman rank correlation test (SPSS 9.0TM; Chicago, IL,
USA; P ≤ 0.05).
Results
Structural chromosomal aberrations in RA
In 4 of 21 patients with RA (19%), structural chromosomal
aberrations were observed in P-1 or P-4 SFB, with involve-
ment of chromosome 1 in 3 of 4 cases (Supplementarymaterial). Structural aberrations of the chromosomes 15 and
X were also observed in one patient each. In P-1 skin FB,
only a breakage of chromosome 5 was observed in one RA
patient (Supplementary material). The enlarged secondary
constriction observed on the long arm of chromosome 16 in
all PBL and SFB metaphases of one RA patient is a known
morphological variant without pathologic relevance (Supple-
mentary material). In compliance with ISCN guidelines [28],
only clonal structural aberrations occurring in more than one
cell (i.e. the composite deletion in chromosome 15) were
reported in the cytogenetic findings (Table 1).
Numerical chromosomal aberrations in RA
Peripheral blood lymphocytes
Findings for PBL were normal in all the RA patients for
whom karyotype analysis was performed (Table 1).
Synovial fibroblasts
First-passage SFB from 10 of the 18 RA patients for
whom karyotype analysis was performed (56%) displayed
numerical chromosomal aberrations involving chromo-
somes 4, 6, 7, 8, 9, 12, 18, and Y (Table 1). Until P-4,
there was an increase of both the proportion of affected
patients (8 of 8; 100%) and the percentage of SFB
showing gains or losses of whole chromosomes (Table 1).
Chromosome 7 was the chromosome predominantly
affected (in 10 of 10 patients at P-1, and in 7 of 8 patients
at P-4). (Note that data sets are not complete for all
patients due to limited sample availability and the paucity
of mitoses in some cell cultures.)
Quantitative comparison of the mean levels of
polysomies or monosomies ex vivo and in vitro in RA
In synovial tissue of RA patients, the mean percentages for
polysomies of chromosomes 4, 6, 8, 9, and 18 did not
exceed threshold levels of 4% (Fig. 1) [31]. The mean per-
centages for monosomies of chromosomes 7 and 18 did
not exceed threshold levels of 7% (Fig. 1) [31].  In P-1
SFB, threshold levels were exceeded for polysomies of
chromosomes 6, 7, 8, and 9. In P-4 SFB, threshold levels
were exceeded for monosomy 18 and for polysomies of
chromosomes 6, 7, 8, 9, and 18 (Fig. 1). Isolated SFB
strongly contributed to polysomy 7 in synovial tissue.
The percentage of +7 SFB increased between P-1 and P-
4, indicating a selective growth advantage for 7-polysomic
SFB in vitro (Fig. 1). The percentage of SFB monosomic
and polysomic for chromosome 18 also increased until P-
4 (5.0-fold and 4.6-fold, respectively). The percentage of
monosomic SFB was always higher than that of polysomic
SFB, indicating a growth advantage of 18-monosomic
SFB in vivo and in vitro in RA (Fig. 1).
The percentage of cells with trisomic nuclei was generally
lower than that with polysomic nuclei, indicating that both
chromosomal nondisjunction and endoreduplication con-
tribute to the ex vivo and  in vitro aberrations (Fig. 1;
shaded bars).
Structural chromosomal aberrations in OA
In 9 of 24 OA patients (38%), structural chromosomal
aberrations were observed in P-0 synovial cells or P-1/P-4
SFB, with involvement of chromosome 1 in 4 of 9 cases
(e.g. chrb(1)(q12)[2]; Supplementary material). Structural
aberrations of chromosomes 8, 9, 11, and 12 were also
observed in one patient each, and aberrations of chromo-
somes 5 and 7 were observed in two patients. In one OA
patient, a deletion in the long arm of chromosome 1 was
also detected in P-4 skin FB (Supplementary material).
Two clonal aberrations (chromosomes 9 and 16) were
observed in PBL of OA patients (Supplementary material).
However, the clonal deletion in the long arm of chromo-
some 9 was not confirmed in a larger number of
metaphases; also, the fragile site at q22.1 of chromosome
16 is a known morphological variant, without pathologic
relevance.
Numerical chromosomal aberrations in OA
Peripheral blood lymphocytes
Except for one patient with karyotype 45,X[10]/46,XX[17],
i.e. a mosaic form of the Turner syndrome, cytogenetic
findings for PBL were normal in all OA patients (Table 2).
Synovial fibroblasts
In 18 of 24 OA patients (75%), early-passage SFB
showed numerical chromosomal aberrations involving
chromosomes 4, 5, 6, 7, 8, 9, 12, 18, and X (Table 2).
Until P-4, both the proportion of affected patients (12 of
13; 92%) and the percentage of synovial fibroblasts
showing chromosome gains or losses increased (Table 2).
As in RA, chromosome 7 was the one predominantly
affected (in 17 of 18 patients in P-1, and 12 of 13 in P-4).
Quantitative comparison of the mean levels of
polysomies or monosomies ex vivo and in vitro in OA
The mean percentages for polysomies of chromosomes 4,
6, 8, 9, and 18 and for monosomies of chromosomes 7
and 18 did not exceed (or only marginally exceeded) the
threshold levels (Fig. 2). In P-1 SFB, threshold levels were
exceeded for monosomy 18 and for polysomies of chro-
mosomes 4 and 7; in P-4 SFB, threshold levels were
exceeded for polysomies of chromosomes 4, 6, 7, 8, and
9 (Fig. 2). Isolated SFB (P-1 18.4%; n = 15) strongly con-
tributed to polysomy 7 in synovial tissue.
As in RA, the percentage of +7 SFB increased until P-4,
and the percentage of SFB monosomic for chromosome
18 was always higher than the percentage of SFB
polysomic for chromosome 18 (Fig. 2).
The percentage of cells with trisomic nuclei was generally
lower than that with polysomic nuclei, indicating that both
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Table 1
Cytogenetic findings in various cells/nuclei from patients with rheumatoid arthritis
Karyotype and FISH resultsa
Peripheral Nuclei  Synovial fibroblasts
blood extracted  from  Collagenase 
Patient lymphocytes synovial tissueb digest P-1 P-4
ES43 46,XX n.a. n.a. 46,XX n.a.
ES51 46,XX n.a. n.a. 47,XX,+7[9]/46,XX [41] n.a.
ES79 46,XY n.a. n.a. 46,XY n.a.
L07 46,XY n.a. n.a. 46,XY n.a.
L12 46,XY n.a. n.a. 46,XY n.a.
VS01 46,XY n.a. n.a. 46,XY n.a.
AA5 n.a. n.a. n.a. n.a. 
FISH:+6[23%];+7[19%];+8[17%]; n.a.
+9[18%];incl. polyploid [11%]
EB1 46,XY n.a. n.a. 46,XY n.a.
EB2 46,XX n.a. n.a. 46,XX n.a. 
FISH:+6[16%];+7[31%];+8[22%];
+9[20%];incl. polyploid [14%]
EB4 46,XX n.a. n.a. n.a. 46,XX 
FISH:+7[33%];+8[12%];
-9[15%];+18[9%];-18[11%]; 
incl. polyploid [4%]
EB5 46,XY n.a. n.a. 46,XY,del(15)(q22),-21,+mar  46,XY (Passage 6) 
[cp3]/46,XY[2] 
FISH:+6[5%];+7[11%];-8[8%];  FISH:+7[6%];+8[10%];+9[6%]; 
+9[6%];incl. polyploid [2%] incl. polyploid [4%]
EB6 46,XX FISH:+6[7%];+7[12%]; n.a. 47,XX,+7[6];46,XX[6]  n.a. 
+8[2%];-8[0%];-18[8%]; FISH:+6[3%];+7[40%];+8[5%];  FISH:+6[13%];+7[58%];+8[8%]; 
incl. polyploid [1%] -8[8%];-18[9%] -8[4%];-18[84%]; incl. polyploid [2%]
EB7 n.a. FISH:+6[6%];+7[3%];  n.a. 46,XY (1/12 metaphases 45,X,-Y)  46,XY (1/10 metaphases 45,X,-Y,+7?) 
-18[9%];+/-Y[n.a.];  FISH:+6[n.a.];+7[5%];-18[8%];  FISH: :+6[n.a.];+7[4%];-18[n.a.]; 
incl. polyploid [1%] -Y[5%];+Y[4%];  -Y[30%];+Y[0%]
incl. polyploid [2%]
EB20 46,XY  FISH:+7[2%];+12[5%] 46,XY 46,XY  n.a.
FISH:normal FISH:+7[4%];  FISH:+7[9%];+12[14%];
+12[5%] incl. polyploid [1%]
EB23 46,XX n.a. 46,XX  46,XX  46,XX 
FISH:normal FISH:+7[4%];  FISH:+7[9%];+9[5%];+18[2%] FISH:+7[13%];+9[11%];+18[7%]
+9[3%];+18[1%]
EB25 46,XX  FISH:+8[5%] n.a. 46,XX n.a.
FISH:normal FISH:normalchromosomal nondisjunction and endoreduplication con-
tribute to the ex vivo and  in vitro aberrations (Fig. 2;
shaded bars).
Comparison of ex vivo and in vitro findings for
individual patients
Numerical chromosomal aberrations observed in RA and
OA tissue as a whole (i.e. in nuclei extracted from the syn-
ovial membrane; Tables 1 and 2) showed good corre-
spondence with the findings in the collagenase digest (i.e.
in adherent synovial cells after in vitro culture for approxi-
mately 8–9 days), or in isolated, P-1 SFB (in vitro culture
for approximately 14 days).
Numerical chromosomal aberrations in other joint
diseases
Peripheral blood lymphocytes
PBL of patients with other rheumatic diseases showed no
cytogenetic abnormalities (Supplementary material).
Synovial fibroblasts
Polysomy 7 was observed in P-1 (2%) and P-4 (4%) SFB
of one patient with ankylosing spondylitis (see Supple-
mentary material).
Limited degree of chromosomal aberrations in normal
joints or patients with joint trauma
The cytogenetic findings for nuclei extracted from synovial
tissue, mixed synovial cells (collagenase digest), or P-1
SFB of four control patients were normal. Upon extended
in vitro culture, however, polysomies of several chromo-
somes exceeding the threshold levels appeared in SFB of
two patients with joint trauma (JT) (in P-4 after 148 days of
culture in one patient, and in P-1 after 21 days in the
other). The mean percentage of trisomic nuclei/cells was
well below the threshold levels for all samples (including
P-4 SFB) and chromosomes (Supplementary material).
Numerical chromosomal aberrations in skin fibroblasts
in RA and OA
The mean percentages for polysomies of chromosomes 4,
6, 7, and 9 and for monosomy 7 in P-1 skin FB from
normal subjects or RA and OA patients did not exceed
threshold levels (Supplementary material). Until P-4, the
mean percentage of polysomic skin FB increased (possi-
bly reflecting culture artifacts), exceeding threshold levels
for chromosome 6 in RA and for chromosomes 4, 6, 7,
and 9 in OA. The mean percentages of nuclei trisomic for
chromosomes 4, 6, 7, and 9 were well below threshold
levels in P-1 or P-4 skin FB derived from normal subjects
or RA and OA patients (Supplementary material).
Correlations among cytogenetic findings, and between
cytogenetic findings and clinical parameters
A significant positive correlation between the percentages
of polysomies for chromosome 7 in collagenase digest and
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.P-1 SFB in both RA (n = 5; P = 0.028; ρ = 0.918) and OA
(n = 11;  P = 0.031;  ρ = 0.648) underlined good corre-
spondence of ex vivo and in vitro data (Tables 1 and 2).
Significant positive correlations between the disease dura-
tion in RA patients and the levels of polysomies in P-1
SFB for chromosomes 6 (n = 5;  P = 0.014;  ρ = 0.947)
Arthritis Research    Vol 3 No 5 Kinne et al
Figure 1
Numerical chromosomal aberrations in the RA synovial membrane. Polysomy (hatched bars) and trisomy (shaded bars) of the individual
chromosomes are depicted as means ± SEM for n = 7–13 patients. Polysomies in synovial tissue of RA patients exceeded threshold levels
(broken lines) only in the case of chromosome 7. In P-1 synovial fibroblasts (FB), threshold levels were exceeded for polysomies of chromosomes
6, 7, 8, and 9. In P-4 synovial FB, threshold levels were exceeded for polysomies of chromosomes 6, 7, 8, 9, and 18 and monosomy 18; there was
a clear increase between P-1 and P-4. Considering only trisomic nuclei, only aberrations in the numbers of chromosome 7 exceeded threshold
levels, even in P-4 synovial FB. P-0 = primary culture; P-1 = passage 1; P-4 = passage 4.and 8 (n = 4; P = 0.050; ρ = 0.949) indicated a possible
link between the chronicity of disease and the occurrence
of numerical aberrations.
An influence of the inflammatory activity on the occurrence
of polysomies was suggested by a significant positive cor-
relation between levels of polysomy for chromosome 7 in
Available online http://arthritis-research.com/content/3/5/319
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Figure 2
Numerical chromosomal aberrations in the OA synovial membrane. Bars as in Fig. 1 (means ± SEM for n = 10–16 patients). Polysomies (hatched
bars) in OA synovial tissue only exceeded threshold levels (broken lines) in the case of chromosome 7, except for a very marginal increase for
chromosome 8. In P-1 synovial FB, polysomies for chromosomes 4 and 7 and monosomy 18 were above threshold levels; in P-4 synovial FB,
polysomies for chromosomes 4, 6, 7, 8, and 9 were above threshold levels. Considering only trisomic nuclei (shaded bars), numerical chromosomal
aberrations were observed for chromosome 7 only, except for a limited elevation of trisomy 8 in P-4 synovial FB. P-0 = primary culture; P-1 =
passage 1; P-4 = passage 4.A
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Table 2
Cytogenetic findings in various cells/nuclei from patients with osteoarthritis
Karyotype and FISH resultsa
Peripheral Nuclei  Synovial fibroblasts
blood extracted  from  Collagenase 
Patient lymphocytes synovial tissueb digest P-1 P-4
ES37 46,XY n.a. n.a. 47,XY,+7[1]/46,XY[49] 47,XY,+7[2]/46, XY[48]
ES52 46,XX n.a. n.a. 46,XX n.a.
ES53 46,XY n.a. n.a. 46,XY n.a.
ES54 46,XX n.a. n.a. 46,XX n.a.
L09 46,XX n.a. n.a. 47,XX,+7[12]/48,XX,+7,+8[5];46,XX[33] n.a.
L11 46,XX n.a. n.a. 46,XX n.a.
EB8 46,XY  FISH:+7[4%];+8[4%]; 46,XY  n.a.
FISH:normal +9[3%];-18[7%]; incl. polyploid [1%] n.a. FISH:+7[17%];+8[7%];+9[9%]; -18[19%]
EB9 46,XX n.a. n.a. 47,XX,+7[2]  n.a.
FISH:normal FISH:+7[52%]; -9[4%] FISH:+7[n.a.]; -9[25%]
EB10 46,XX n.a. n.a.  46,XX  n.a.
FISH:normal FISH:+6[6%]; +7[20%];+8[11%];  FISH:+7[32%];
-8[2%];-18[8%] -8[10%];-18[18%]
EB11 46,XX  FISH:+4[3%];+7[8%]; n.a.  47,XX,+7[3]/46,XX[7]  47,XX,+7[3]/46,XX[6]
FISH:normal +18[0%] FISH:+4[3%];  FISH:+4[7%];+7[15%];+18[8%]; 
+7[19%];+18[2%] incl. polyploid [7%]
EB12 45,X[10]/  FISH:+4[0%];+7[12%];  n.a. 47,XX,+7,+4 or +5[3]/46,XX[4]  46,XX 
46,XX[17] +8[12%];+9[4%] FISH:+4[4%];+7[42%];+8[0%];  FISH:+4[2%];+7[36%];+8[1%]; 
FISH:-X[32%] +9[11%] +9[6%]
EB13 46,XY n.a. n.a.  46,XY  46,XY 
FISH:normal FISH:+7[15%];  FISH:+7[37%];-9[8%]; FISH:+4[8%];
-9[3%];+12[0%] +12[11%] +7[16%]; +9[5%];-9[25%];+12[6%]
EB14 46,XX  FISH:+7[14%];+8[0%]; n.a.  47,XX,+7[3]/46,XX[7]  46,XX,+7,+8,-15,-21[1]/48,XX, 
FISH:normal +X[4%] FISH:+7[10%];  FISH:+7[36%];+8[2%];+X[0%] +7,+9[1]/47,XX,+7[1]/48,X,+7,+8,
+8[0%];+X[6%] +9[1]/46,X,-X,+7,-17,+mar[1]/46, 
XX,t(5;11)(q23;q12)[1]/48,X,-X, 
+5,+7,+8[1]/46,XX[1] 
FISH:+7[34%];+8[8%];+X[6%]
EB15 46,XX n.a. n.a. 46,XX  n.a. 
FISH:normal FISH:+6[7%];+7[10%];+8[7%];  FISH:+6[12%];+7[16%];+8[7%]; 
+9[10%];incl. polyploid [7%] +9[10%];incl. polyploid [4%]
EB16 46,XX n.a. n.a.  n.a. n.a. 
FISH:normal FISH:+6[5%]; +7[18%]; FISH:+6[26%];+7[26%];+8[35%]; 
+8[0%]; -X[18%] +X[17%];incl. polyploid [17%]A
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Table 2
Continued
Karyotype and FISH resultsa
Peripheral Nuclei  Synovial fibroblasts
blood extracted  from  Collagenase 
Patient lymphocytes synovial tissueb digest P-1 P-4
EB17 46,XX n.a. 46,XX,chrb(1)(q12) 46,XX  n.a.
FISH:normal [2]/46,XX[4]  FISH:+4[16%];+6[6%];+12[5%]; 
FISH:+4[17%];  incl. polyploid [1%]
+6[3%];+12[1%]
EB18 46,XX n.a. 46,XX  46,XX  n.a. 
FISH:normal FISH:+7[1%];  FISH:+7[5%];+8[4%];+9[1%] FISH:+7[18%];+8[18%]; 
+8[0%];+9[2%] +9[18%];incl. polyploid [3%]
EB19 46,XX  FISH:+7[18%];+8[2%]; 46,XX  47,XX,+7[2]/46,XX[7]  47,XX,+7[2]/46,XX[6] 
FISH:normal +9[4%];+12[4%];  FISH:+7[14%];  FISH:+7[10%];+8[0%];+9[4%];  FISH:+7[26%];+8[18%];+9[7%]; 
incl. polyploid [2%] +8[0%];+9[0%]; +12[7%] +12[8%];incl. polyploid [7%]
+12[0%]
EB21 46,XX n.a. 46,XX  46,XX  n.a. 
FISH:normal FISH:+4[17%];  FISH:+4[3%];+6[3%];+7[5%];  FISH:+4[3%];+6[4%];+7[11%]; 
+6[7%];+7[11%];  +9[3%]; incl. polyploid [1%] +9[3%]; incl. polyploid [3%]
+9[17%]; incl. polyploid [5%]
EB22 46,XY n.a. n.a.  46,XY  n.a 
FISH:normal FISH:+4[4%]; +7[7%]; FISH:+4[2%];+7[6%];+9[1%];  FISH:+4[8%];+7[8%]; +9[7%]
+9[3%]; incl. polyploid [1%] incl. polyploid [1%]
EB24 46,XX  FISH:+4[0%];+6[3%]; n.a.  46,XX  n.a. 
FISH:normal +7[7%];+9[3%] FISH:+4[8%];  FISH:+4[9%];+6[2%];+7[33%];  FISH:+4[2%];+6[2%];+7[24%]; 
+6[8%];+7[25%]; +9[8%]; +9[3%];incl. polyploid [2%] +9[3%];incl. polyploid [2%]
incl. polyploid [7%]
EB29 46,XX n.a. n.a. n.a. n.a.
FISH:normal
J4 n.a. FISH:+4[5%];+7[14%]; n.a. 46,XX  46,XX
incl. polyploid [1%] FISH:+4[1%];7[6%]; incl. polyploid [1%]
J5 n.a. FISH:+4[5%];+7[13%] n.a. n.a.  n.a.
FISH:+4[1%]; +7[15%] FISH:+4[1%];+7[20%]
aSee Table 1. bOnly FISH data are available. incl. = including; n.a. = not analyzed (Karyotype and/or FISH); P-1 = passage 1; P-4 = passage 4.RA collagenase digests and the serum concentrations of
C-reactive protein (n = 5; P = 0.041; ρ = 0.894).
The lack of significant correlations between the levels of
polysomy for any chromosome in RA SFB and concurrent
treatment with methotrexate is in contrast to results in pre-
vious reports [32,33], thereby questioning a clear-cut
influence of methotrexate treatment in this study.
None of the other clinical parameters, including the ages
of patients with RA and OA, showed any correlation with
the occurrence or the percentages of chromosomal aber-
rations (data not shown).
Discussion
Structural chromosomal aberrations
Structural aberrations of various chromosomes occur in
isolated SFB from RA and OA patients, as reported in
other chronic rheumatic disorders [34–36]. Although
mostly nonclonal, a striking proportion of the structural
chromosomal aberrations (del and chrb) in SFB of both
RA (three of four) and OA (four of nine) patients was
found on chromosome 1, affecting regions q12, q13,
q21, and q31. Benign mesenchymal neoplasms do not
show any unbalanced chromosomal abnormalities in
these regions on chromosome 1 [34], whereas malignant
mesenchymal neoplasms, e.g. chondrosarcoma, osteo-
sarcoma, or pleomorphic sarcoma, carry such unbal-
anced chromosomal abnormalities (der or del), with a
focus on q11 (26 cases), q12 (10 cases), and q21 (16
cases) [34]. Whether this is a pure coincidence and
whether the location of genes (such as those encoding
cathepsins S and K and the Fc receptor CD64) on 1q21
implies functional consequences for SFB remain matters
for further investigation.
Specificity of chromosomal aberrations for RA
Numerical aberrations were observed in SFB of patients
with RA, OA, or ankylosing spondylitis, with a similar spec-
trum of affected chromosomes. In RA and OA, however,
chromosome 7 was the one predominantly affected. This
observation expands and confirms similar findings in non-
purified synovial cells in RA [12–15], villonodular synovitis
[13], and OA [16,19]. As previously observed [19], the
proportion of patients with +7 and the percentage of
cells/nuclei with trisomy/polysomy 7 were significantly
higher in OA than in RA, concerning both synovial tissue
(11.9%; n = 7 versus 5.9%; n = 7; P ≤ 0.05) and collage-
nase digest (16.2%; n = 13 versus 6.2%; n = 5; P ≤ 0.05).
In addition, +7 (or general tetraploidy [37]) seems to be
linked to a number of non-neoplastic diseases/tissues
unrelated to joint inflammation, including chronic
pyelonephritis and focal steatosis of the liver [12]. Thus,
mosaic +7 likely does not bear any specificity for RA. On
average, polysomy 7 was not observed in PBL or P-1 skin
FB of the patients. This excludes that there was a general-
ized chromosomal mosaic in all somatic cells.
Functional aspects of trisomy 7
Chromosome 7 carries a number of potentially relevant
genes (for example, cytokines/growth factors and their
receptors, transcription factors, signal-transduction mole-
cules, and molecules involved in matrix formation and
cell–extracellular matrix [38]) implying functional conse-
quences for +7 SFB. Indeed, both RA and OA SFB with
+7 appeared to have a selective growth advantage
(Tables 1 and 2; Figs 1 and 2), confirming previous find-
ings [14,15]. Whether gains of chromosomes result in
overexpression of target genes on these chromosomes
apparently depends on individual cases ([39,40] and our
own preliminary results on the expression of the proto-
oncogene c-met [hepatocyte growth factor receptor
encoded on 7q31]). The hypothesis that genes located on
human chromosome 7 (or other chromosomes showing
aberrations in the present study) may be linked to RA sus-
ceptibility is being addressed also by other groups, for
example, by analyzing quantitative trait loci in the homolo-
gous chromosomal regions of intercrosses of inbred
mouse or rat strains susceptible or resistant to the induc-
tion of experimental arthritis [41,42]. Also, potential sus-
ceptibility loci [43] or single nucleotide polymorphisms in
potentially disease-relevant genes [44] are being
assessed by genomewide screening in RA patients.
Parallel occurrence of different polysomies
This study also confirms the parallel presence of different
trisomies, as has previously been described in villonodular
synovitis (+5,+7) [13], RA (+7,+8) [14], OA (+5,+7) [19],
and Dupuytren’s contracture (+7,+8) [17]. While these
findings may reflect a general chromosomal instability, the
predominance of the effect in chromosome 7 argues for a
biased instability.
Conclusion
The findings in RA patients were numerical chromosomal
aberrations, i.e. trisomy or polysomy 7 and monosomy 18,
and structural aberrations, particularly in chromosome 1.
These alterations were limited to the synovial compartment:
skin FB and blood lymphocytes were virtually normal.
However, the alterations were not specific for RA; similar
ones were seen in OA and spondylarthropathy. Thus, such
alterations may not be functional to a particularly aggres-
sive phenotype of RA SFB, but rather reflect a common
response to inflammatory/microenvironmental stimuli in
rheumatic diseases. Because JT/control samples were vir-
tually normal, it appears that chromosomal alterations may
be associated with chronic pathology of the joints.
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Supplementary material
Supplementary materials and methods
Patients
Inflamed synovial tissue, heparinized peripheral blood, and
skin samples from the edge of the surgical incision were
obtained from RA patients (n = 21), OA patients (n = 24),
and patients (n = 8) with various inflammatory/degenerative
joint diseases (three spondylarthropathies, comprising one
ankylosing spondylitis and two psoriatic arthritis; one villon-
odular synovitis; one systemic lupus erythematosus; one
juvenile rheumatoid arthritis; one undifferentiated
monoarthritis; and one reactive arthritis) (Supplementary
Table 1). The patients were classified according to the cri-
teria of the American College of Rheumatology/American
Rheumatism Association or the European Spondy-
larthropathy Study Group [20–24]. As controls, synovial
tissue/cells from four patients with either no joint disease
(postmortem samples) or recent joint trauma as well as skin
samples (taken during plastic surgery) from four normal
donors were studied (Supplementary Table 1). The groups
were generally gender-matched, since no significant differ-
ences were observed among groups for gender distribu-
tion, except for a significant difference between the
spondylarthropathy group (containing 3 male patients) and
the OA group (containing 19 female and 5 male patients)
(P ≤ 0.005). Because of limited availability of patient/donor
material, groups were not strictly age-matched, with the
result that the RA patients studied were significantly
younger than OA patients, and that the patients in both of
these groups were older (P ≤ 0.05) than patients with
spondylarthropathy, JT/normals, and normal skin donors.
Due to the lack of correlation between the age of the
patients and the occurrence or the percentages of chromo-
somal aberrations, however, this was not considered to
question the validity of the results. No significant differ-
ences were observed for the disease duration among RA,
OA, and spondylarthropathy patients. As expected, serum
concentrations of C-reactive protein were significantly
higher in RA than in OA patients (Supplementary Table 1).
Synovial tissue, peripheral blood, and skin were obtained
during open joint replacement/traumatology surgery or
arthroscopic synovectomy at the Department of Orthope-
dics, University of Leipzig; the Clinic of Orthopedics, Bad
Düben; the Clinic of Orthopedics, Friedrich Schiller Uni-
versity Jena (Eisenberg); the Department of Traumatology,
Friedrich Schiller University Jena, Germany; and the
Department of Orthopedic Surgery, University of Michi-
gan, Ann Arbor, MI, USA. The study was approved by the
ethics committees of the respective universities. Paired
blood samples were immediately transferred to the Insti-
tutes of Human Genetics in Jena or Leipzig for lymphocyte
culture and karyotype/FISH analysis. Synovial tissue and
skin were placed in cell culture medium at ambient tem-
perature and digested within 2 h.
Tissue digestion, cell culture, and fibroblast isolation
Synovectomy samples of synovial membranes were finely
minced and digested for 30 min at 37°C in PBS contain-
ing 0.1% trypsin (Sigma, Deisenhofen, Germany), fol-
lowed by digestion in 0.1% collagenase P (Boehringer
Mannheim, Mannheim, Germany) in DMEM/10% FCS;
(both Gibco BRL, Eggenstein, Germany) for 2 h at 37°C,
in a 5% CO2 atmosphere. After two washes with serum-
free DMEM, the cells were cultured in DMEM/10% FCS,
25 mM HEPES, penicillin (100 U/ml), streptomycin
(100 µg/ml), amphotericin B (2.5 mg/ml), and gentamycin
(0.1 mg/ml) (all Gibco BRL). The medium was changed
after 1 day, and then every 2 or 3 days, to remove nonad-
herent cells from the culture. After 7 days of primary
culture, the adherent cells were trypsinized (in 0.25%
trypsin/0.2% EDTA; Gibco BRL), removed from the
culture dish by mechanical dislocation, washed in
PBS/2% FCS, and used for negative isolation. The
samples were randomly tested to exclude Mycoplasma
contamination using a commercially available ELISA kit
(Boehringer Mannheim).
Negative isolation of FB was performed as described else-
where [25]. Briefly, primary culture synovial cells were
incubated with Dynabeads® M-450 CD14 (clone RMO52;
Dynal, Hamburg, Germany) in PBS/2% FCS for 1 h at
Arthritis Research    Vol 3 No 5 Kinne et al4°C, under bidirectional rotation. Conjugated and unconju-
gated cells were separated using the magnetic particle
concentrator Dynal® and, after two washes in PBS/2%
FCS, either analyzed by fluorocytometry with the mono-
clonal antibodies mentioned below or cultured to P-4 by
1:3 split at confluency.
Primary-culture skin FB from normal donors (kindly pro-
vided by Dr D Sauer, plastic surgeon, Leipzig, Germany)
were prepared by first incubating skin samples with
Dispase II (0.5 U/ml; Boehringer Mannheim) overnight at
4°C and, after removal of the epidermis, by digesting with
0.25% collagenase P (Boehringer Mannheim) in
DMEM/1% FCS at 37°C and 5% CO2 for 4 h. The result-
ing cell suspension was then cultured as above.
Fluorocytometry
FACS (fluorescence-activated cell sorting) analyses of iso-
lated SFB were performed according to standard proce-
dures as described elsewhere [26]. The specificity of
staining was confirmed using isotype-matched control
monoclonal antibodies at identical concentrations. Analy-
ses were performed on a FACScan® (Becton Dickinson,
San Jose, CA, USA). Gates were set to include all viable
cells and to exclude 99% of the cells stained with control
immunoglobulins. Unconjugated cells obtained from the
primary culture of the synovial membrane by negative iso-
lation with Dynabeads® M-450 CD14 showed an enrich-
ment of SFB (Thy-1+: RA 72.1%, n = 13; OA 71.5%,
n = 15; and prolyl 4-hydroxylase+: RA 80.3%, n = 9; OA
93.1%,  n = 9), with a contamination of <2% macro-
phages (CD14+, CD68+, CD11b+) and <1% T cells, B
cells, plasma cells, natural killer cells, dendritic cells, or
polymorphonuclear neutrophil leucocytes [25].
GTG-banding and fluorescence in situ hybridization
Cytogenetic studies of PBL were performed according to
standard methods (RPMI medium with 10% FCS and 1.2%
phytohemagglutinin in a 72-h culture). For cytogenetic
studies of primary-culture synovial cells (collagenase digest;
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Supplementary Table 1
Clinical characteristics of the subjects at the time of synovectomy/sampling
Subjects Gender  Age Disease  RF  ESR  CRPa  No. of ARA  Concomitant 
(n) (M/F) (years) duration (years) (+/–) (mm/h) (mg/l) criteria (RA) medication (n)
Rheumatoid arthritis
21 10/11 63.1 ± 2.0 10.7 ± 2.1 14/4 36.6 ± 5.2 41.4 ± 7.8 5.1 ± 0.2 Methotrexate (10)
(n.d.=1) (n.d.=3) (n.d.=3) (n.d.=1) Prednisolone (16)
Sulfasalazine (4)
Gold salts (1)
NSAIDs (14)
Osteoarthritis
24 5/19 69.5 ± 2.3 9.3 ± 3.0 0/6 18.4 ± 3.7 6.4 ± 1.1 0.3 ± 0.1 Prednisolone(1)
(n.d.=15) (n.d.=18) (n.d.=2) (n.d.=1) NSAIDs (11)
none (13)
Spondylarthropathy
3 3/0 37.0 ± 12.5 3.8 ± 3.1 0/3 22.3 ± 12.8 24.4 ± 19.4 1.0 ± 1.0 Sulfasalazine (1)
NSAIDs (2)
none (1)
Other arthritides
L02 / VNS  F 64 4 – 18 <5 0 Methotrexate, NSAIDs
L04 / SLE F 38 7 – 11 28.9 3 Methotrexate, 
Prednisolone
ES36 / JRA M 18 14 – 4 <5 2 Chloroquine, NSAIDs
ES63 / UA M 18 1 – 2 <5 0 NSAIDs
EB32 / ReA M 43 8 n.d. 60 8.5 1 none
Joint trauma/normals
4 2/2 49.3 ± 9.5 0.5 ± 0.5 n.d. n.d. n.d. 0.0 ± 0.0 none (4)
Normal skin
4 1/3 20.3 ± 10.7 0.0 ± 0.0 n.d. n.d. n.d. 0.0 ± 0.0 none (4)
aNormal range, <5 mg/l. +/– = positive/negative; ARA = American Rheumatism Association (now American College of Rheumatology); 
AS = ankylosing spondylitis; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; JRA = juvenile rheumatoid arthritis; n.d. = not
determined; NSAIDs = nonsteroidal anti-inflammatory drugs. RA = rheumatoid arthritis; ReA = reactive arthritis; RF = rheumatoid factor; SLE =
systemic lupus erythematosus; UA = undifferentiated monoarthritis; VNS = villonodular synovitis. For the parameters age, disease duration, ESR,
CRP, and number of ARA-Criteria (RA), values are means ± SEM; for the other parameters, values are numbers (n).i.e. adherent synovial cells), SFB (P-1; P-4) or skin FB (P-1
and P-4; for culture times, see Supplementary Table 2),
cells were seeded at a density of 1 × 105 cells/glass slide in
QuadriPERM wells (Heraeus, Hanau, Germany). At near
confluency, cells were treated with colcemid (1 µg/ml) for
1.75 h, followed by hypotonic treatment with 0.2%
MgCl2/0.4% sodium citrate solution for 10 min, both at
37°C. The cells were fixed with three changes of
methanol/acetic acid (3:1; 10 min each; room temperature)
and air-dried under laminar flow. GTG-banding was per-
formed according to standard protocols [27] on 10–50
metaphases per case. Karyotypes were described in accor-
dance with ISCN 1995 [28]. Structural aberrations occur-
ring in one cell only, i.e. nonclonal events, are reported for
the sake of general interest but are not included in the kary-
otype (Tables 1 and 2; Supplementary Tables 3 and 4).
Extraction of nuclei from formalin-fixed/paraffin-embedded
or cryofixed tissue was performed in accordance with the
methods of  Liehr et al [29 and 30, respectively]. FISH for
the analysis of the copy number of particular chromo-
somes in interphase nuclei was performed according to
standard protocols (VYSIS, Downers Grove, IL, USA) by
applying fluorescence-labeled, repetitive, α-satellite DNA
probes (VYSIS) specific for the centromeric region of
each chromosome. In most cases, centromere probes for
four different chromosomes were used per case, selected
on the basis of numerical aberrations detected by GTG
banding. One hundred cells/sample were examined apply-
ing dual-color FISH. A cutoff gate of 4% for chromosome
gains and of 7% for chromosome losses was set, i.e.
higher than previously published for leukemia [31], in
order to account for the unknown tissue investigated and
to consider only those values abnormal, which exceeded
variations in cells from normal tissue. In cases in which ex
vivo data (i.e. nuclei extracted from synovial tissue) or data
from mixed synovial cells (collagenase digest) could be
compared with in vitro data of SFB (P-1 or P-4), paired
values were included/reported even if they did not reach
the cutoff level (Tables 1 and 2; Figs 1 and 2; Supplemen-
tary Figs 1–3).
Data were analyzed and depicted either on the basis of
the total polysomy of nuclei, i.e. irrespective of the under-
lying mechanism, and pointed to the total gain of potential
gene transcription units, or selectively, on the basis of
trisomic nuclei, focusing on mitotic nondisjunction as a
possible underlying mechanism.
Statistical analysis
Because of multiple comparisons, the data were first sub-
jected to the multi-group Kruskal–Wallis test. The nonpara-
metric Mann–Whitney U test was then applied to analyze
differences between data of different disease groups. The
Spearman rank correlation test was used to analyze corre-
lations among parameters and between these parameters
and the clinical status/treatment of individual patients. In all
cases, differences were considered statistically significant
for  P ≤ 0.05. Analyses were performed using the SPSS
9.0TM program (SPSS Inc, Chicago, IL, USA).
Supplementary results
Numerical chromosomal aberrations in other joint
diseases
Peripheral blood lymphocytes
PBL of patients with several other rheumatic diseases
showed no cytogenetic abnormalities, as assessed by
GTG-banding (Supplementary Table 5).
Synovial fibroblasts
Numerical chromosomal aberrations were observed, i.e.
polysomy 7 in P-1 (2%) and P-4 (4%) SFB from one
patient with ankylosing spondylitis, indicating that the
aberrations in SFB are not restricted to RA and OA but
rather are a possible common feature of chronic rheumatic
diseases (Supplementary Table 5).
Limited degree of chromosomal aberrations in normal
joints or patients with joint trauma
Nuclei extracted from synovial tissue, collagenase digest, and
synovial fibroblasts
In four control patients (two with JT and two with normal
joints), the nuclei extracted from synovial tissue or P-1
Arthritis Research    Vol 3 No 5 Kinne et al
Supplementary Table 2
Culture time (days) of synovial cells in primary culture (collagenase digest), synovial fibroblasts, and skin fibroblasts from patients
with rheumatoid arthritis, osteoarthritis, and joint trauma, or normal donors 
Synovial fibroblasts Skin fibroblasts
Synovial cells
Source of cells (collagenase digest) Passage 1 Passage 4 Passage 1 Passage 4
Rheumatoid arthritis  9.2 ± 3.3 (n = 5) 13.8 ± 1.8 (n = 9) 81.1 ± 9.9 (n = 7) 46.2 ± 20.7 (n = 6) 63.5 ± 19.5 (n = 2)
Osteoarthritis 8.1 ± 1.2 (n = 14) 13.9 ± 1.7 (n = 17) 91.4 ± 9.0 (n = 11) 18.0 ± 2.0   (n = 14) 62.4 ± 5.8   (n = 13)
Joint trauma  n.a. 28.0 ± 7.0 (n = 2) n.a. n.a. n.a.
Normal subjects  n.a. n.a. n.a. 20.0 ± 8.9  (n = 3) n.a.
Values are shown as means ± SEM. n.a. = not analyzed.Supplementary Table 3
Structural chromosomal aberrations in rheumatoid arthritis
Karyotype
Peripheral Synovial fibroblasts Skin fibroblasts
blood
Chromosome lymphocytes Passage 1 Passage 4 Passage 1 Passage 4
1 46,XY,del(1)(q31),  46,XY,del(1)(q12 or q13),
t(5,8,6)(p11;p11.2;p11.1), -3,-19,+mar1, 
del(11)(p14),-18,+20[1] +mar2[1]
46,XY,chrb(1q?21)[1]
5 46,XY,chrb(5)(q10)[1]
15 46,XY,del(15)(q22),-21, 
+mar[cp3]
16 46,XX,16qh+ 46,XX,16qh+
X 46,XX,chrb(X)(q11)[1]
Supplementary Table 4
Structural chromosomal aberrations in osteoarthritis
Karyotype
Peripheral Synovial fibroblasts Skin fibroblasts
blood
Chromosome lymphocytes Passage 1 Passage 4 Passage 1 Passage 4
1 46,XX,del(1)(q23),  46,XX,chrb(1)(q23)[1] 46,XX,del(1)(q11 or q12)[1]
t(3;7)(q23;q34),-21, (Collagenase  digest)
+mar[1]
48,XX,+del(1),+7,+9[1]  
46,XX,chrb(1)(q12)[2] 
(Collagenase digest)  
46,X,-X,+7, chrb(1)(q12)[1]
2 46,XX,t(2;10)(q14;q22)[1]
5 46,XX,del(5)(p13)[1] 46,XX,t(5;11)(q23;q12)[1]
7 46,XX,t(7;12)(p14;q13)[1]   46,XY,del(7)(q32)[1]
47,XX,+del(7) 46,XX,-2,+4,-6,-8,+15, 
(q11.1→qter)[1] +add(7)(p22)[1]
8 46,XY,-4,+7,t(8;11)
(p11.2;p11.2)[1]
9 46,XX,del(9)(q11)[2] 46,XX,chrb(9)(q13)[1]
46,XX,chrb(9)(q21)[1]
11 45,X-X,-10,inv(11) 46,XX,t(11;15)[1] 
(p15.5;q23.3),+mar[1] (Collagenase-digest)
12 46,XX,chrb(12q?13)[1]
(Collagenase-digest)
16 46,XY,fra(16)(q22.1)[2]
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Table 5). Upon extended in vitro culture, however,
polysomies of multiple chromosomes exceeding the
threshold levels appeared in P-4 SFB from one JT patient
(148 days culture) and in P-1 SFB from another JT patient
(21 days culture; Supplementary Tables 2 and 5).
The mean percentages for polysomies of chromosomes 4,
6, 7, and 9 in normal/JT synovial tissue and collagenase
digest did not exceed the threshold levels (4% for
polysomies and 7% for monosomies). The same was true
for monosomy of chromosome 7 (Supplementary Fig. 1).
The mean percentages of SFB polysomic for chromo-
somes 4, 6, 7, and 9 equally increased until P-4, leading
to levels above threshold for these chromosomes in P-4
(Supplementary Fig. 1).
If instead of all polysomic nuclei only trisomic nuclei were
considered, the mean percentage of nuclei/cells with
aberrations was well below the threshold levels for all
samples (including P-4 SFB) and chromosomes (Supple-
mentary Fig. 1; shaded bars).
Arthritis Research    Vol 3 No 5 Kinne et al
Supplementary Figure 1
Numerical chromosomal aberrations in the normal/JT synovial membrane. Polysomy (hatched bars) and trisomy (shaded bars) of the individual
chromosomes in extracted nuclei from synovial tissue, nonseparated synovial cells (collagenase digest), and isolated synovial fibroblasts (FB; P-1,
P-4) are shown as means ± SEM of n = 1–3 patients. The mean percentages of polysomies in normal/JT synovial tissue, collagenase digest, and
P-1 synovial FB did not exceed threshold levels (broken lines). In P-4, the mean percentages of synovial FB polysomic for chromosomes 4, 6, 7,
and 9 were elevated to levels above threshold. If instead of all polysomic nuclei, only trisomic nuclei were considered, there was no elevation of
chromosomal aberrations above threshold levels, not even in P-4 synovial FB. P-0 = primary culture; P-1 = passage 1; P-4 = passage 4.Direct comparison between numerical chromosomal
aberrations in the synovial membrane of patients with
RA, OA, and joint trauma or normal joints
While chromosome 6 showed almost no numerical aberra-
tions (with the exception of an increased level of polysomy
6 in P-1 RA SFB), both OA and RA synovial tissue
showed significant more polysomy 7 than did normal/JT
tissue, with a significantly higher value in OA than in RA
(11.9%; n = 7 versus 5.9%; n = 7; P ≤ 0.05; Supplemen-
tary Fig. 2). A significant difference between RA and OA
was also observed in the collagenase digest (Supplemen-
tary Fig. 2).
Isolated SFB from RA patients (12.4%; n = 10) and OA
patients (18.4%; n = 15) strongly contributed to the
polysomy 7 observed in nuclei from synovial tissue and
collagenase digest (containing a mixture of synovial cells).
These findings were also confirmed if only trisomic nuclei
were considered (Supplementary Fig. 2).
Numerical chromosomal aberrations in skin fibroblasts
of patients with RA or OA and of normal controls
To answer the question of whether the cytogenetic aberra-
tions observed in SFB were limited to the synovial com-
partment, paired skin FB from RA and OA patients and
skin FB from normal donors were analyzed. In 2 of 5 RA
patients analyzed and in 15 of 16 OA patients analyzed,
polysomies above threshold were observed in P-1 or P-4
skin FB, with chromosomes 6, 9, and 12 being involved in
RA, and chromosomes 4, 6, 7, 8, 9, 12, 18, and X in OA
(GTG-banding/FISH; Supplementary Table 6). Until P-4,
the percentage of skin FB showing chromosome gains or
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Supplementary Figure 2
Comparison of numerical chromosomal aberrations in the RA, OA, and normal/JT synovial membrane. Polysomy (hatched bars) and trisomy
(shaded bars) of the individual chromosomes in extracted nuclei from synovial tissue, nonseparated synovial cells (collagenase digest), and isolated
synovial fibroblasts (FB; P-1) are depicted as means ± SEM of n = 5–18 patients. #P ≤ 0.05 versus normal/JT for the comparison of polysomies;
* P ≤ 0.05 versus RA for the comparison of polysomies. While chromosome 6 showed almost no numerical aberrations (with the exception of an
increased level of polysomy 6 in P-1 RA synovial FB), both OA and RA synovial tissue showed a significant elevation of polysomy 7 in comparison
with normal/JT tissue, with a significantly higher value in OA than in RA. A significant difference between RA and OA was also observed in
nonseparated synovial cells (P-0).Arthritis Research    Vol 3 No 5 Kinne et al
Supplementary Figure 3
Comparison of numerical chromosomal aberrations in skin fibroblasts of RA and OA patients and of normal donors. Polysomy (hatched bars) and
trisomy (shaded bars) of the individual chromosomes in skin fibroblasts (P-1, P-4) are depicted as means ± SEM of n = 3–14 patients. On average,
skin fibroblasts from RA and OA patients and from normal donors did not show any polysomies/trisomies above threshold levels, except for
hyperdiploid nuclei upon extended culture (P-4), which may reflect culture artifacts.
Supplementary Table 5
Cytogenetic findings in various cells/nuclei from subjects with various joint disorders and normal joints
Karyotype/FISH
Peripheral Nuclei Synovial  fibroblasts
Subject/ blood extracted  from 
diagnosis lymphocytes synovial tissue Passage 1 Passage 4
ES45/AS 46,XY n.a. 47,XY,+7[1]/46,XY[49] 47,XY,+7[2]/46,XY[48]
L05/PsA 46,XY n.a. 46,XY n.a.
ES60/PsA 46,XY n.a. 46,XY n.a.
L02/VNS 46,XX n.a. 46,XX n.a.
L04/SLE 46,XX n.a. 46,XX n.a.
ES36/JRA 46,XY n.a. 46,XY 46,XY
ES63/UA 46,XY n.a. 46,XY n.a.
EB32/ReA n.a. n.a. FISH:normal n.a.
J1/JT (1 month culture) n.a. n.a. 46,XX FISH:normal 46,XX FISH:+4[8%];+6[7%]; 
+7[9%];+9[8%]; 
incl. polyploid [6%]
J2/JT (3 weeks culture) n.a. FISH:normal 46,XX n.a.
FISH:+9[5%];+10[5%];
incl. polyploid [2%]
FISH:normal 
(synovial cells in collagenase digest)
SynS7/Nor. (paraffin sections) n.a. FISH:normal n.a. n.a.
B1/Nor. (cryostat sections) n.a. FISH:normal n.a. n.a.
AS = ankylosing spondylitis; JRA = juvenile rheumatoid arthritis; JT = joint trauma; n.a. = not analyzed (Karyotype and/or FISH); Nor. = normal; 
PsA = psoriasis arthritis; ReA = reactive arthritis; SLE = systemic lupus erythematosus; UA = undifferentiated monoarthritis; VNS = villonodular
synovitis.losses increased (Supplementary Table 6). Such numeri-
cal chromosomal aberrations were not observed in P-1
skin FB from normal donors.
Although clearly above the threshold levels in individual
patients (Supplementary Table 6), the mean percentages
for polysomies of chromosomes 6 and 7 in P-1 skin FB
from normal subjects or RA and OA patients did not
exceed threshold levels (Supplementary Fig. 3). This was
also the case for polysomy of chromosomes 4 and 9, as
well as monosomy 7 (Supplementary Table 6).
Until P-4, the mean percentage of polysomic skin FB
increased, exceeding threshold levels for chromosome 6
in RA and for chromosomes 4, 6, 7, and 9 in OA.
If, instead of all polysomic nuclei, only trisomic nuclei were
considered, the mean percentages of numerical aberra-
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Supplementary Table 6
Cytogenetic findings in skin fibroblasts from patients with rheumatoid arthritis and osteoarthritis or unaffected normal controls
Karyotype/FISH
Subject/diagnosis Passage 1 Passage 4
EB20/RA 46,XY; FISH:normal 46,XY; FISH:+6[6%];+12[8%];
incl. polyploid [2%]
EB25/RA 46,XX; FISH:+6[6%];+9[6%]; n.a.
incl. polyploid [1%]
EB26/RA 46,XY; FISH:normal n.a.
EB27/RA 46,XX; FISH:normal n.a.; FISH:normal
EB28/RA 46,XY; FISH:normal 46,XY
EB9/OA 46,XX; FISH:+7[6%];+8[7%] n.a.
EB10/OA 46,XX: FISH:+7[7%];+8[7%] 46,XX; FISH:+8[9%];-18[8%]
EB11/OA 46,XX; FISH:+18[8%] 46,XX; FISH:normal
EB12/OA 46,XX 46,XX; FISH:+9[6%])
EB13/OA 46,XY; FISH:normal n.a.; FISH:+4[18%];+7[17%];+9[9%];
+12[10%];incl. polyploid [8%]
EB14/OA n.a. 47,XX,+7[5]/46,XX[3]; FISH:+7[5%];
+8[5%];+9[6%];+X[8%];
incl. polyploid [2%]
EB15/OA 46,XX; FISH:+7[6%];+9[6%]; 47,XX,+7[2]; FISH:+6[16%];+7[45%];
incl. polyploid [4%] +8[15%];+9[23%];incl. polyploid [15%]
EB16/OA 46,XX; FISH:+6[10%];+7[10%];+8[22%]; n.a.
+X[24%];incl. polyploid [8%]
EB17/OA 46,XX; FISH:normal 46,XX; FISH:+4[10%];+6[10%];+8[11%];
+12[11%];incl. polyploid [9%]
EB18/OA 46,XX; FISH:+8[5%] 46,XX; FISH:normal
EB19/OA n.a.; FISH:normal 46,XX; FISH:+7[7%];+8[7%];+9[6%];
+12[10%];incl. polyploid [3%]
EB21/OA 46,XX; FISH:normal 46,XX; FISH:+4[5%];incl. polyploid [1%]
EB22/OA 46,XY; FISH:normal 46,XY; FISH:+4[11%];+6[13%];+7[12%];
+9[11%];incl. polyploid [10%]
EB24/OA n.a.; FISH:+4[7%];+7[7%]; 46,XX; FISH:+4[23%];+6[24%];+7[22%];
incl. polyploid [1%]. +9[24%];incl. polyploid [22%]
EB29/OA n.a.; FISH:normal n.a.
J5/OA n.a.; FISH:+4[5%];incl. polyploid [3%] n.a.; FISH:+4[5%];+6[7%];+7[5%];
+9[7%];incl. polyploid [5%]
LZ1/Nor n.a.; FISH:normal n.a.
LZ2/Nor 46,XX; FISH:normal n.a.
LZ3/Nor 46,XY; FISH:normal n.a.
LZ5/Nor 46,XY n.a.
Nor = normal; OA = osteoarthritis; RA = rheumatoid arthritis; n.a. = not analysed (Karyotype and/or FISH).tions for chromosomes 6, 7 (Supplementary Fig. 3;
shaded bars), 4, and 9 were well below threshold levels in
P-1 or P-4 skin FB derived from RA patients, OA patients,
or normal subjects.
On average, therefore, skin FB from RA and OA patients
did not show any polysomies above threshold levels,
except for hyperdiploid nuclei after extended culture (P-4),
which probably reflects culture artifacts.
Supplementary discussion
Functional aspects of numerical chromosomal
aberrations
Although not specific for RA, the occurrence of mosaic +7
in SFB may have functional consequences for rheumatic
diseases, inasmuch as this chromosome carries a number
of potentially relevant genes. These include cytokines/
growth factors and their receptors (e.g. platelet-derived
growth factor-alpha chain, IL-6, epidermal growth factor,
insulin-like growth factor, hepatocyte growth factor and its
receptor); transcription factors (e.g. ETV1, SP4, cAMP-
response element binding protein); signal-transduction
molecules (e.g. the catalytic subunit of phospatidylinositol
3-kinase-gamma, protein-tyrosine phosphatase-zeta,
human tyrosine kinase and its receptor); and molecules
involved in matrix formation and cell–extracellular matrix
contact (e.g. the α2-chain of collagen I and the beta-1 inte-
grin subunit), among others [38]. Indeed, both RA and OA
SFB with +7 appeared to have a selective growth advan-
tage (as shown by the increase of the percentage of +7
SFB from P-1 to P-4; Tables 1 and 2; Figs 1 and 2). This
finding is consistent with those in previous studies, in
which up to 50% of the cells had +7 by P-10 to P-14
([13,14]; in the present study, mean of 23% in P-10, n = 2
RA SFB).
Interestingly, a selective growth advantage seems to be
conferred not only by +7, but also by several other numeri-
cal chromosomal aberrations (Tables 1 and 2). In RA, for
example, an in vitro expansion of SFB with +6, +8, +9,
+18, –18, and –Y was observed in individual cases
(Table 1; Fig. 1). In OA, such expansion was noted in SFB
with +4, +6, +8, +9, and –9 (Table 2; Fig. 2). Whether the
presence/disruption of key regulatory genes of the cell
cycle, such as oncogenes (homologues), transcription
factors, and tumor-suppressor genes on these chromo-
somes [15,18,38] favors growth in vitro remains to be
determined. Selective growth advantages of cells with
chromosomal aberrations may therefore be relevant for the
interpretation of future studies with SFB.
Whether gains of chromosomes result in overexpression
of target genes on these chromosomes apparently
depends on the individual case. For example, a coinci-
dence of trisomy 7 and overexpression of epidermal
growth factor has been reported in Barrett’s esophagus
[39]. On the other hand, lack of overexpression of the
proto-oncogene ets-2, encoded on chromosome 21, in
heart tissue of patients with Down syndrome provides evi-
dence against a gene-dosage effect of polysomies [40].
Our own preliminary results from polymerase chain reac-
tions show that the expression of the proto-oncogene c-
met (hepatocyte growth factor receptor; encoded on
7q31) is considerably stronger in OA than in RA synovial
tissue, providing further support for dissociation of
polysomy and expression of a target gene (manuscript in
preparation).
Extent of numerical chromosomal aberrations
Since it is technically impossible to perform GTG-banding
on interphase nuclei extracted from synovial tissue and
since normally centromere probes for only four different
chromosomes were used per case (on the basis of numeri-
cal aberrations detected by GTG banding), the present
study does not yet provide a complete assessment of chro-
mosomal aberrations in synovial tissue and SFB from
inflamed joints. Therefore, the extent of chromosomal aber-
rations may have been underestimated, leaving open the
possibility of an even higher degree of aberrations in vivo.
Correlation of aberrations with clinical parameters and
methotrexate treatment
Concurrent treatment may also play a role in the occur-
rence of chromosomal alterations. Indeed, repeated
and/or high-dose application of methotrexate can induce
hepatic fibrosis or cytogenetic damage (e.g. multinucle-
ated binucleated cells and chromosomal aberrations
[32,33]). In the present study, two of the four RA patients
with structural chromosomal aberrations (irrespective of
the affected chromosome), and two of the three RA
patients with structural aberrations of chromosome 1, had
been concurrently treated with methotrexate, raising the
possibility that the treatment may have contributed to the
occurrence of such alterations. On the other hand, there
was no significant correlation between the levels of
polysomy for any chromosome in RA SFB and concurrent
treatment with methotrexate, raising the question of
whether there was a clear-cut influence of the treatment.
Comparison of ex vivo and in vitro findings
The present study shows that limited cultivation of adher-
ent cells for 7 days, subsequent isolation of SFB, and
rapid analysis of chromosomal aberrations does not
greatly alter the cytogenetic status of the cells. Therefore,
this previously published technique of isolating SFB from
primary culture [25], by analyzing cells with few replication
cycles, proves helpful in limiting the influence of in vitro
growth selection and/or exposure to culture media.
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